

**Confidential and archived draft**  
**Ozone therapy as adjuvant in oncology.**  
**Drafted by Dr. Wayne McCarthy – May 1, 2023**

**Story of the document**

This draft, presented by ISCO3 member Dr. Wayne, was submitted for the opinion of all members, following the established procedure.

**Legal Opinion**

The Legal Advisor Roberto Quintero, submitted (July 13, 2023, copy attached) a legal opinion proposing "that it is neither prudent nor advisable for ISCO3 to publish an official document specifically dedicated to cancer".

The following members said the following:

Serhiy Danylkov. Fri, Jul 14, 2023. "Many thanks for sharing. Absolutely agree!"

Bernardino Clavo. Jul 17, 2023. "Although I suggested comments and ideas for improving the document, I showed my concerns about the manuscript.

"I agree with the Legal Advisor, Roberto Quintero. I would like to highlight two of its last comments:

"It is neither prudent nor advisable for ISCO3 to publish an official document specifically dedicated to cancer, due to the negative administrative/judicial consequences that would arise against ozone therapists..."

"It is not an opportune moment for the publication of the paper".

However, I expect we have not to wait many years more to do it."

Wayne McCarthy, Jul 27, 2023. "Thank you for your email outlining your legal opinion on ozone in Oncology. All of us would like to see a better way forward for ozone treatment out in the world where it is much needed. Under the circumstances I do agree with your opinion. I appreciate what Adriana has been through (as well as you) and I believe the people have a strong demand for its use and will continue to seek it out. Oncology is an edifice uncompromising in suppressing challenges to its monopoly. People seek it out though, this won't stop so we work in the clinics to relieve suffering every day. I took 3 months off to research and write that draft which helped me immensely to overcome the sorrow felt from witnessing the passing of several beloved people close to us. We know we don't have a cure (even though some patients do pull through and survive), we do believe Ozone is one of the best therapies out there. We know we help immensely to ease suffering."

**Medical opinion**

The scientific secretary Adriana Schwartz (July 14, 2023, copy attached) pointed out that "it seems to me that in these things we must keep a low profile" and "and "as Scientific Committee we must act with great sense, strategy and prudence in order to move forward."

The following members said the following:

Heinz Konrad, 14 jul 2023. "I agree with you, one must keep a low profile."

Wayne McCarthy, 16 jul 2023. "I completely agree with your very considered approach and nuanced strategy for moving forward. I understand that the SOP Ozone in Oncology will be lodged in the members section of the ISCO3 website for private access only for our members. That feels really good to me. Deep appreciation to you as you weathered the storm and never gave up your principals. We move forward together in strength."

Jaime Cachay Agurto, Jul 17, 2023. "I agree with the point of view of Dr. Adriana and Dr. Bernardino Calvo. In the treatment of cancer, therapeutic proposals must be based on evidence, even though in practice many integrative therapies have some utility. I support and agree with the decision NOT to sign the SOP. I appreciate the effort made by Dr. Wayne, his work is interesting."

**Eventually the President of the committee decided (July 15, 2023)**

"As per the "SOP LEG/00/04 Procedures to approve ISCO3 documents" dated November 30, 2017 ([www.isco3.org](http://www.isco3.org)). I declare: Archived for only confidential use, the document: ISCO3/CLI /00/14. Ozone therapy as adjuvant in oncology. Drafted by Dr. Wayne McCarthy.

"This document will be archived for the sole confidential use of ISCO3 members, and be pending until the results of clinical studies with more data are presented in the scientific literature or until the political situation around the subject became more favorable. Thanks to all the members who participated in the debate and to the authors of the original. I attach a copy of the final draft of confidential material ISCO3/CLI /00/14. The attached material may not be disseminated outside the framework of ISCO3 members."